Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide.

We have determined the crystal structures of the ligand binding domain (LBD) of the rat vitamin D receptor in ternary complexes with a synthetic LXXLL-containing peptide and the following four ligands: 1alpha,25-dihydroxyvitamin D(3); 2-methylene-19-nor-(20S)-1alpha,25-dihydroxyvitamin D(3) (2MD); 1alpha-hydroxy-2-methylene-19-nor-(20S)-bishomopregnacalciferol (2MbisP), and 2alpha-methyl-19-nor-1alpha,25-dihydroxyvitamin D(3) (2AM20R). The conformation of the LBD is identical in each complex. Binding of the 2-carbon-modified analogues does not change the positions of the amino acids in the ligand binding site and has no effect on the interactions in the coactivator binding pocket. The CD ring of the superpotent analogue, 2MD, is tilted within the binding site relative to the other ligands in this study and to (20S)-1alpha,25-dihydroxyvitamin D(3) [Tocchini-Valentini et al. (2001) Proc. Natl. Acad. Sci. U.S.A. 98, 5491-5496]. The aliphatic side chain of 2MD follows a different path within the binding site; nevertheless, the 25-hydroxyl group at the end of the chain occupies the same position as that of the natural ligand, and the hydrogen bonds with histidines 301 and 393 are maintained. 2MbisP binds to the receptor despite the absence of the 25-hydroxyl group. A water molecule is observed between His 301 and His 393 in this structure, and it preserves the orientation of the histidines in the binding site. Although the alpha-chair conformer is highly favored in solution for the A ring of 2AM20R, the crystal structures demonstrate that this ring assumes the beta-chair conformation in all cases, and the 1alpha-hydroxyl group is equatorial. The peptide folds as a helix and is anchored through hydrogen bonds to a surface groove formed by helices 3, 4, and 12. Electrostatic and hydrophobic interactions between the peptide and the LBD stabilize the active receptor conformation. This stablization appears necessary for crystal growth.

[1]  A. Kolinski,et al.  2-Ethyl and 2-ethylidene analogues of 1alpha,25-dihydroxy-19-norvitamin D(3): synthesis, conformational analysis, biological activities, and docking to the modeled rVDR ligand binding domain. , 2002, Journal of medicinal chemistry.

[2]  B. Konety,et al.  Vitamin D and prostate cancer. , 2002, The Urologic clinics of North America.

[3]  D. Moras,et al.  Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  T. Okano,et al.  History of the development of new vitamin D analogs: studies on 22-oxacalcitriol (OCT) and 2β-(3-hydroxypropoxy)calcitriol (ED-71) , 2001, Steroids.

[5]  C. Hayes.  Vitamin D: a natural inhibitor of multiple sclerosis , 2000, Proceedings of the Nutrition Society.

[6]  L. Freedman,et al.  Mechanisms of gene regulation by vitamin D(3) receptor: a network of coactivator interactions. , 2000, Gene.

[7]  M. Lazar,et al.  The DRIP Complex and SRC-1/p160 Coactivators Share Similar Nuclear Receptor Binding Determinants but Constitute Functionally Distinct Complexes , 2000, Molecular and Cellular Biology.

[8]  N. Weigel,et al.  Vitamin D and Prostate Cancer , 1999, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[9]  R J Fletterick,et al.  Structure and specificity of nuclear receptor-coactivator interactions. , 1998, Genes & development.

[10]  H. DeLuca,et al.  New 1alpha,25-dihydroxy-19-norvitamin D3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl, and 2-methylene analogues. , 1998, Journal of medicinal chemistry.

[11]  H. DeLuca,et al.  Current understanding of the molecular actions of vitamin D. , 1998, Physiological reviews.

[12]  A. Vagin,et al.  MOLREP: an Automated Program for Molecular Replacement , 1997 .

[13]  R. St-Arnaud,et al.  Evidence for ligand-dependent intramolecular folding of the AF-2 domain in vitamin D receptor-activated transcription and coactivator interaction. , 1997, Molecular endocrinology.

[14]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[15]  H. DeLuca,et al.  Salt concentration determines 1,25-dihydroxyvitamin D3 dependency of vitamin D receptor-retinoid X receptor--vitamin D-responsive element complex formation. , 1997, Archives of biochemistry and biophysics.

[16]  E. Kalkhoven,et al.  AF-2 activity and recruitment of steroid receptor coactivator 1 to the estrogen receptor depend on a lysine residue conserved in nuclear receptors , 1997, Molecular and cellular biology.

[17]  R. Day,et al.  Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer. , 1995, Urologic oncology.

[18]  William Bourguet,et al.  Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α , 1995, Nature.

[19]  R. Bouillon,et al.  Structure-function relationships in the vitamin D endocrine system. , 1995, Endocrine reviews.

[20]  P. Chambon,et al.  Activation function 2 (AF‐2) of retinoic acid receptor and 9‐cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF‐2 activity. , 1994, The EMBO journal.

[21]  Collaborative Computational,et al.  The CCP4 suite: programs for protein crystallography. , 1994, Acta crystallographica. Section D, Biological crystallography.

[22]  M. Mol,et al.  Topical calcitriol in the treatment of chronic plaque psoriasis: a double‐blind study , 1993, The British journal of dermatology.

[23]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[24]  J. Lemire.  Immunomodulatory role of 1,25‐dihydroxyvitamin D3 , 1992, Journal of cellular biochemistry.

[25]  M. Galligan,et al.  Baculovirus-mediated expression of the human vitamin D receptor. Functional characterization, vitamin D response element interactions, and evidence for a receptor auxiliary factor. , 1991, The Journal of biological chemistry.

[26]  L. Binderup,et al.  20-epi-vitamin D3 analogues: a novel class of potent regulators of cell growth and immune responses. , 1991, Biochemical pharmacology.

[27]  H. DeLuca,et al.  Overproduction of rat 1,25-dihydroxyvitamin D3 receptor in insect cells using the baculovirus expression system. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[28]  N. Ikekawa.  Structures and biological activities of vitamin D metabolites and their analogs , 1987, Medicinal research reviews.

[29]  N. Walworth,et al.  Effect of 1α,25-dihydroxyvitamin D3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions , 1986 .

[30]  H. DeLuca,et al.  Identification of the porcine intestinal 1,25-dihydroxyvitamin D3 receptor on sodium dodecyl sulfate/polyacrylamide gels by renaturation and immunoblotting. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Kuroki,et al.  Regulation of Terminal Differentiation of Cultured Mouse Epidermal Cells by lα,25-Dihydroxyvitamin D3 , 1983 .

[32]  E. Abe,et al.  1 alpha,25-Dihydroxycholecalciferol and a human myeloid leukaemia cell line (HL-60). , 1982, The Biochemical journal.

[33]  H. Sakagami,et al.  Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[34]  F. Glorieux,et al.  Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. , 1980, The New England journal of medicine.

[35]  Goldstein Da,et al.  Is calcitriol [1,25(OH)2D3] harmful to renal function? , 1979 .

[36]  W. Kabsch.  A solution for the best rotation to relate two sets of vectors , 1976 .

[37]  A. Norman,et al.  STUDIES ON VITAMIN D AND ITS ANALOGS PART 7, SOLUTION CONFORMATIONS OF VITAMIN D3 AND 1ALPHA,25-DIHYDROXYVITAMIN D3 BY HIGH-RESOLUTION PROTON MAGNETIC RESONANCE SPECTROSCOPY , 1975 .

[38]  C. Chothia.  Structural invariants in protein folding , 1975, Nature.

[39]  A. Norman,et al.  Vitamin D: concerning the relationship between molecular topology and biological function. , 1974, Proceedings of the National Academy of Sciences of the United States of America.

[40]  H. DeLuca,et al.  Pathogenesis of Hereditary Vitamin-D-Dependent Rickets , 1973 .

[41]  B. Lee,et al.  The interpretation of protein structures: estimation of static accessibility. , 1971, Journal of molecular biology.

[42]  M. Brentani,et al.  Antiproliferative effects of 1,25-dihydroxyvitamin D3 on breast cells: a mini review. , 2002, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[43]  H. DeLuca,et al.  A potent analog of 1alpha,25-dihydroxyvitamin D3 selectively induces bone formation. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[44]  W. Delano.  The PyMOL Molecular Graphics System , 2002 .

[45]  D. Moras,et al.  The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. , 2000, Molecular cell.

[46]  P. Chambon,et al.  Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. , 1995, Nature.

[47]  S. Massry,et al.  Is calcitriol [1,25(OH)2D3] harmful to renal function? , 1979, JAMA.